ESTRO 35 Programme book & Exhibition guide

MONDAY 2 MAY 2016

Symposium with Proffered Papers ADAPTIVE RADIOTHERAPY FOR COPINGWITH ANATOMICAL VARIATIONS: HOPE OR HYPE? 08:45 - 10:00 | ROOM 2 A huge step in radiation therapy is the introduction of Adaptive Radiotherapy (ART). With ART the treatment can be individualised, according to changes in the anatomy of the patient. To date the clinical implications are not yet known; several studies are developed to get more information concerning these clinical implications. In this symposium, we will focus on different ART strategies, selection of the patients, as well as the practical challenges and costs of ART. Chair: M. Mast (The Netherlands) Co-chair: G. Guidi (Italy) 08:45 > Overview of clinical practice of ART for pelvic tumours Speaker: S. Thörnqvist (Norway), L.B. Hysing, L. Tuomikoski, A. Vestergaard, K. Tanderup, L.P. Muren, B.J.M. Heijmen

SP-0392

09:05 > The challenges of ART from a physician's perspective Speaker: S. Nuyts (Belgium)

SP-0393

09:25 > The practical “costs” of adaptive radiotherapy Speaker: C. Rowbottom (UK)

SP-0394

09:45 > Patient selection in head and neck adaptive radiotherapy

C. Brouwer (The Netherlands), R. Steenbakkers, A. Van der Schaaf, C. Sopacua, L. Van Dijk, R. Kierkels, H. Bijl, J. Burgerhof, J. Langendijk, N. Sijtsema

OC-0395

Symposium with Proffered Papers TIME IS NOT ON OUR SIDE: CARDIOVASCULAR TOXICITY AFTER RADIOTHERAPY 08:45 - 10:00 | ROOM 4 Radiotherapy is often used in patients with expected prolonged disease-free-survival. Long term follow up of cancer survivors, indicated that the therapeutic effect of radiotherapy is compromised by cardio- vascular disease (CAD) aggravated by radiation exposure of the heart and coronary arteries. Recent publications have shown a dose-effect relationship with no apparent threshold. In this multidisciplinary symposium we will discuss the clinical aspects of CAD along with quantitative analyses beyond the QUANTEC and whether the use of innovative techniques compared to conventional radiation will change the magnitude of radiation induced CAD. Impotently, we will show that in 2016 we still have open questions. Chair: O. Kaidar-Person (Israel) Co-chair: C. Fiandra (Italy) 08:45 > The risk of cardiovascular disease after breast cancer treatment: the clinician's point of view Speaker: C. Taylor (UK)

SP-0396

SCIENTIFIC PROGRAMME | PROGRAMME AND EXHIBITION GUIDE

121